Table 1 Demographic, clinical parameters and outcomes of patients with anti-GBM disease

Age (years)

35.3±15.7

Gender (male/female)

32/14

Hydrocarbon exposure, n (%)

3/44 (6.8%)

Prodromal infection, n (%)

19/46 (41.3%)

Smoking, n (%)

24/45 (53.3%)

Hemoptysis, n (%)

15/46 (32.6%)

Oliguria/anuria, n (%)

14/46 (30.4%)

Gross hematuria, n (%)

15/31 (32.6%)

Nephrotic syndrome, n (%)

19/31 (61.3%)

Serum creatinine at presentation (μmol/L)

728.5±378.8

Level of anti-GBM antibodies (U/mL) median (range)

63 (15, 176)

Positive with ANCA, n (%)

9/46 (19.6%)

Hemoglobin (g/L)

85.6±26.1

Percentage of crescents in glomeruli (%)

78.8±29.6

Cellular crescents (%)

60.3±33.8

Fibrotic crescents (%)

33.2±31.0

Renal survival (1 year), n (%)

10/46 (21.7%)

Patient survival (1 year), n (%)

36/46 (78.3%)